Aim Immunotech (AIM): CEO bought ~$3.2K
Thomas K Equels, CEO at Aim Immunotech, bought ~$3.2K of Aim Immunotech shares.
- ~$3.2K
- Approx. value · 20K sh @ $0.156
- 210K
- Holds after · shares reported
- Traded
- Nov 6, 2026
- Filed
- Nov 6, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Sep 3, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them
- Sep 8, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them
- Sep 14, 2026Insider · First insider buy since Jun 2025CEO purchased ~$1.3K of AIM shares in the open market
- Sep 15, 2026InsiderCEO purchased ~$4.9K of AIM shares in the open market
- Sep 16, 2026InsiderCEO purchased ~$2.3K of AIM shares in the open market
- Sep 17, 2026InsiderCEO purchased ~$5K of AIM shares in the open market
- Oct 22, 2026InsiderCEO purchased ~$5.1K of AIM shares in the open market
- Oct 23, 2026InsiderCEO purchased ~$5.1K of AIM shares in the open market
- Nov 6, 2026 · this disclosureInsiderCEO purchased ~$3.2K of AIM shares in the open market
What came next
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Aim Immunotech
For Aim Immunotech, OQRO holds 11 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AIM page.
Other recent filings by Thomas K Equels, CEO & President
- SEC Form 4 at Aim Immunotech (AIM)Nov 13, 2026
- SEC Form 4 at Aim Immunotech (AIM)Nov 12, 2026
- SEC Form 4 at Aim Immunotech (AIM)Nov 10, 2026
- SEC Form 4 at Aim Immunotech (AIM)Nov 9, 2026
- SEC Form 4 at Aim Immunotech (AIM)Oct 26, 2026
The full history of Thomas K Equels, CEO & President is on the profile page.
How this filing works
Explore the data
Other disclosures at Aim Immunotech
- SEC Form 4Nov 13, 2026
- SEC Form 4Nov 12, 2026
- SEC Form 4Nov 10, 2026
- SEC Form 4Nov 9, 2026
- SEC Form 4Oct 26, 2026
- SEC Form 4Oct 23, 2026
Everything OQRO holds on this company is on its AIM page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
